{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/ions-stock-analysis/",
 "dataUrl": "https://clearank.com/stock/ions-stock-analysis/data.json",
 "title": "Ionis (IONS) Stock Forecast & Price Target (2026)",
 "description": "Ionis Pharmaceuticals, Inc. (IONS) stock: Healthcare, Biotechnology. $7.9B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Ionis Pharmaceuticals, Inc. (IONS)",
 "published": "2026-07-10T09:33:18+00:00",
 "modified": "2026-09-16T05:16:21.964+00:00",
 "generated": "2026-09-16T11:59:53.667Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "IONS",
  "name": "Ionis Pharmaceuticals, Inc.",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Biotechnology",
  "country": "United States",
  "website": "https://www.ionis.com"
 },
 "quote": {
  "price": 47.25,
  "previousClose": 51.44,
  "change": -4.19,
  "changePercent": -8.15,
  "open": 51.37,
  "high": 51.37,
  "low": 46.72,
  "volume": 6812100,
  "averageVolume": 4096520,
  "marketCap": 7852209214,
  "fiftyTwoWeekHigh": 86.74,
  "fiftyTwoWeekLow": 46.72,
  "marketOpen": false,
  "asOf": "2026-09-16T05:16:21.000Z"
 },
 "statistics": {
  "pe": -19.87394925926914,
  "eps": -3.48,
  "dividendYield": 0,
  "beta": 0.419,
  "priceToSales": 9.779876,
  "priceToBook": 19.374763,
  "revenueTtm": 874092992,
  "grossMargin": 0.9897779054969416,
  "returnOnEquity": -1.05496
 },
 "technicals": {
  "rsi": 7.54,
  "macd": -2.02,
  "sma50": 57.95,
  "sma200": 72.74,
  "rsiSignal": "Oversold",
  "trend": "Bearish",
  "pricePosition": "Bearish",
  "macdSignal": "Bearish",
  "rating": "Bearish"
 },
 "analysis": {
  "rating": "Sell",
  "score": 21,
  "consensus": "Sell",
  "fairValue": 47.25,
  "analystTarget": 85,
  "analystCount": 24,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-16T05:16:21.000Z",
  "priceAtAnalysis": 47.25,
  "volatility": {
   "daily": 2.79,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bearish",
  "conservativeEntry": 48.2,
  "aggressiveEntry": 47.25,
  "stopLoss": 56.11,
  "stopLossPercent": 16.42,
  "targets": [
   45.79,
   43.38,
   40.97
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 27.74,
    "base": 49.85,
    "upside90th": 89.58
   },
   {
    "year": 2028,
    "downside10th": 22.95,
    "base": 52.59,
    "upside90th": 120.47
   },
   {
    "year": 2029,
    "downside10th": 20.1,
    "base": 55.48,
    "upside90th": 153.12
   },
   {
    "year": 2030,
    "downside10th": 18.12,
    "base": 58.53,
    "upside90th": 189
   },
   {
    "year": 2031,
    "downside10th": 16.65,
    "base": 61.74,
    "upside90th": 228.98
   },
   {
    "year": 2032,
    "downside10th": 15.5,
    "base": 65.14,
    "upside90th": 273.75
   },
   {
    "year": 2033,
    "downside10th": 14.57,
    "base": 68.72,
    "upside90th": 324.01
   },
   {
    "year": 2034,
    "downside10th": 13.81,
    "base": 72.49,
    "upside90th": 380.45
   },
   {
    "year": 2035,
    "downside10th": 13.18,
    "base": 76.48,
    "upside90th": 443.82
   },
   {
    "year": 2036,
    "downside10th": 12.64,
    "base": 80.68,
    "upside90th": 514.94
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "IONS Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$51.37",
    "Day Range": "$46.72 to $51.37",
    "Prev Close": "$51.44",
    "Volume": "6.81M",
    "52-Week Range": "$46.72 to $86.74",
    "Market Cap": "$7.85B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis On price-to-sales, the yardstick used here in place of P/E, IONS trades at 9.78x, +164% versus the sector average of 3.70x."
   ]
  },
  {
   "id": "financials",
   "title": "IONS Financial Performance",
   "text": [
    "Analysis: In the last 2 quarters, IONS beat estimates 2 times. However, the stock fell 2 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "IONS Analysis",
   "text": [
    "Ionis Pharmaceuticals (IONS) is trading significantly below its key moving averages, with its price below the 50-day SMA of $57.95 and the 200-day SMA of $72.74, confirming a bearish trend. The Relative Strength Index (RSI) is at an extremely oversold level of 7.54, suggesting a potential for a short-term bounce, but the overall momentum remains weak as indicated by the MACD at -2.02. Volume has been elevated, with the latest volume at 6.81 million, 66.3% above average, indicating strong selling pressure. The current price action and significantly oversold conditions suggest that while a technical rebound is possible, the underlying trend remains bearish without a clear break above key resistance levels.",
    "Analysts forecast revenue growth of 51.00% for next year, which, if achieved, could significantly improve the company's valuation and profitability metrics.",
    "Ionis Pharmaceuticals beat EPS estimates in its most recent reported quarters, indicating operational improvements or successful cost management.",
    "Insiders have sold over $190 million worth of stock versus only $1.5 million in purchases, signaling a strong lack of confidence from management and potentially indicating future headwinds.",
    "The stock's RSI is at an extremely low 7.54, and it is trading significantly below its 50-day and 200-day moving averages ($57.95 and $72.74), indicating strong bearish momentum and potential for further downside.",
    "Ionis Pharmaceuticals (IONS) faces a challenging outlook despite positive analyst sentiment and projected revenue growth. The current price of $47.25 is significantly below the median analyst target price of $85.00, suggesting substantial recovery potential if the company can execute on its growth strategy and address profitability concerns. The projected revenue growth of 51.00% for next year is a key factor that could drive a turnaround. However, the persistent heavy insider selling and significantly oversold technical conditions present immediate headwinds that could delay or derail any recovery, making the near-term trajectory uncertain."
   ],
   "lists": {
    "ProTips": [
     "Given the heavy insider selling exceeding $190 million, investors should closely monitor any further dispositions and management commentary for insights into the company's strategic direction and confidence.",
     "The stock is trading at extremely oversold levels (RSI 7.54), suggesting a potential for a short-term technical bounce. However, this should be viewed with caution given the strong bearish trend and fundamental challenges.",
     "With a high price-to-sales ratio of 9.78 compared to the sector median of 3.7, investors should ensure that future revenue growth significantly outpaces current projections to justify the valuation."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Strong Revenue Growth Projections for Next Year",
     "text": "Analysts forecast revenue growth of 51.00% for next year, which, if achieved, could significantly improve the company's valuation and profitability metrics.",
     "source": "Wall Street Estimates"
    },
    {
     "type": "Bullish",
     "title": "Positive Earnings Surprise in Recent Quarters",
     "text": "Ionis Pharmaceuticals beat EPS estimates in its most recent reported quarters, indicating operational improvements or successful cost management.",
     "source": "Earnings Reports"
    },
    {
     "type": "Bearish",
     "title": "Heavy Insider Selling Pressure",
     "text": "Insiders have sold over $190 million worth of stock versus only $1.5 million in purchases, signaling a strong lack of confidence from management and potentially indicating future headwinds.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "significantly Oversold Technical Conditions",
     "text": "The stock's RSI is at an extremely low 7.54, and it is trading significantly below its 50-day and 200-day moving averages ($57.95 and $72.74), indicating strong bearish momentum and potential for further downside.",
     "source": "Technical Analysis"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Ionis Pharmaceuticals (IONS) exhibits a concerning fundamental picture, with a negative EPS of -$3.48 and a net profit margin of -64.66%, indicating significant losses. The company's price-to-sales ratio stands at 9.78, which is considerably higher than the sector median of 3.7, suggesting the stock is overvalued relative to its sales. While the company's debt-to-equity ratio of 4.98 is high, it is within the context of the sector's average. The negative return on equity of -105.50% further confirms profitability challenges. Despite the weak fundamentals, Wall Street's revenue estimates show a projected 51.00% growth for next year, which, if realized, could begin to improve the valuation metrics.",
    "Ionis Pharmaceuticals (IONS) has shown mixed results in its recent earnings reports. In the quarter to March 2026, the company reported an EPS of -$0.30, beating the estimate of -$0.77 by 61.04%, though the stock price declined by 0.09%. Prior to that, in the quarter to March 2026, EPS was $0.65 against an estimate of $0.42, a 54.76% surprise, but the stock fell 0.91%. This pattern of earnings beats not translating into positive stock performance, coupled with the overall negative EPS trend, suggests that market sentiment is heavily influenced by factors beyond short-term earnings beats.",
    "The primary risk for Ionis Pharmaceuticals (IONS) is the significant insider selling, with over $190 million in dispositions versus minimal purchases, indicating a lack of management confidence. Technically, the stock is significantly oversold with its price far below key moving averages, suggesting continued downward pressure despite potential short-term bounces. Also, the company's current valuation appears stretched relative to its sales and profitability, with a high price-to-sales ratio and negative profit margins, presenting a fundamental risk if revenue growth projections are not met."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "7.85B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "N/A (Negative EPS)"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "-3.48"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "86.74"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "46.72"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bearish RSI Oversold SMA Cross Bearish Price vs SMA Bearish MACD Bearish Moving averages show a lagging Death Cross (50-day: $57.95, 200-day: $72.74), price is trading below the 50-day SMA, RSI at 7.5 suggests oversold conditions; potential bounce setup."
   ],
   "facts": {
    "RSI": "Oversold",
    "SMA Cross": "Bearish",
    "Price vs SMA": "Bearish",
    "MACD": "Bearish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "7.54"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-2.02"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "57.95"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "72.74"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.23",
    "Correlation with Nasdaq 100 (QQQ)": "+0.19",
    "Correlation with Bitcoin (BTC)": "-0.02",
    "Correlation with Gold (XAU)": "+0.12"
   }
  },
  {
   "id": "trade-plans",
   "title": "IONS Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for rally",
    "Higher risk, chasing the move",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (7.5) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$45.79",
    "TARGET 2": "$43.38",
    "TARGET 3": "$40.97",
    "STOP LOSS": "$56.11"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+0.66%",
    "Average Feb return": "-0.52%",
    "Average Mar return": "-5.27%",
    "Average Apr return": "+3.31%",
    "Average May return": "-1.47%",
    "Average Jun return": "+4.88%",
    "Average Jul return": "-3.03%",
    "Average Aug return": "+0.63%",
    "Average Sep return": "+0.77%",
    "Average Oct return": "-1.89%",
    "Average Nov return": "+7.73%",
    "Average Dec return": "+0.41%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "2.79%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in IONS in September 2016 would be worth about $14,882 today, compared with about $35,497 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in IONS today could grow to about $17,075 by 2036 in the base case, with a bull case near $108,982 and a bear case around $2,675. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "IONS Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $58.53 for IONS by 2030 in the base case, from $47.25 today (1.2x over 4 years). The downside path ends near $18.12. These are outcomes of a Monte Carlo simulation run on IONS's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using IONS's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "IONS simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$27.74",
        "$49.85",
        "$89.58"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$22.95",
        "$52.59",
        "$120"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$20.10",
        "$55.48",
        "$153"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$18.12",
        "$58.53",
        "$189"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$16.65",
        "$61.74",
        "$229"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$15.50",
        "$65.14",
        "$274"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$14.57",
        "$68.72",
        "$324"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$13.81",
        "$72.49",
        "$380"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$13.18",
        "$76.48",
        "$444"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$12.64",
        "$80.68",
        "$515"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "NVO Novo Nordisk A/S Sponsored NYSE $42.53 -2.12%",
     "url": "https://clearank.com/stock/novo-nordisk-nvo/"
    },
    {
     "text": "RGNX Regenxbio Inc. NASDAQ $7.95 -8.57%",
     "url": "https://clearank.com/stock/rgnx-stock-analysis/"
    },
    {
     "text": "OFIX Orthofix Medical Inc. NASDAQ $9.09 -0.22%",
     "url": "https://clearank.com/stock/ofix-stock-analysis/"
    },
    {
     "text": "CI The Cigna Group NYSE $288.98 -0.37%",
     "url": "https://clearank.com/stock/cigna-group-ci/"
    },
    {
     "text": "MRK Merck & Co., Inc. NYSE $143.17 -1.16%",
     "url": "https://clearank.com/stock/merck-mrk/"
    },
    {
     "text": "TMO Thermo Fisher Scientific Inc. NYSE $635.29 +3.53%",
     "url": "https://clearank.com/stock/tmo-stock-analysis/"
    },
    {
     "text": "ISRG Intuitive Surgical Inc. NASDAQ $377.16 -0.21%",
     "url": "https://clearank.com/stock/intuitive-surgical-isrg/"
    },
    {
     "text": "SYK Stryker Corp. NYSE $281.50 -0.13%",
     "url": "https://clearank.com/stock/stryker-syk/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "BSX vs MDT Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/bsx-vs-mdt/"
    },
    {
     "text": "AAL vs DAL Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/aal-vs-dal/"
    },
    {
     "text": "SMH vs SOXX Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/smh-vs-soxx/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "IONS Insider Trading Analysis",
   "facts": {
    "Bought": "$1.5M",
    "Sold": "$190.1M",
    "Insiders": "21",
    "Avg Transaction": "$1.7M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in IONS",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Mar 17, 2026",
       "cells": [
        "HOUGEN ELIZABETH L Chief Financial Officer",
        "Sell",
        "225.2K",
        "$16.3M"
       ]
      },
      {
       "label": "Sep 3, 2025",
       "cells": [
        "MONIA BRETT P Chief Executive Officer",
        "Sell",
        "203.8K",
        "$12.3M"
       ]
      },
      {
       "label": "Mar 10, 2026",
       "cells": [
        "MONIA BRETT P Chief Executive Officer",
        "Sell",
        "160.8K",
        "$12.1M"
       ]
      },
      {
       "label": "Feb 2, 2026",
       "cells": [
        "BENNETT C FRANK Officer",
        "Sell",
        "85.1K",
        "$7.1M"
       ]
      },
      {
       "label": "Nov 3, 2025",
       "cells": [
        "GEARY RICHARD S Officer",
        "Sell",
        "90.9K",
        "$6.8M"
       ]
      },
      {
       "label": "Jun 26, 2026",
       "cells": [
        "MONIA BRETT P Chief Executive Officer",
        "Sell",
        "85.6K",
        "$6.8M"
       ]
      },
      {
       "label": "Mar 3, 2026",
       "cells": [
        "BENNETT C FRANK Officer",
        "Sell",
        "85.1K",
        "$6.7M"
       ]
      },
      {
       "label": "Dec 28, 2023",
       "cells": [
        "PARSHALL B LYNNE Director",
        "Sell",
        "117.6K",
        "$5.9M"
       ]
      },
      {
       "label": "May 4, 2026",
       "cells": [
        "LOSCALZO JOSEPH Director",
        "Sell",
        "77.3K",
        "$5.8M"
       ]
      },
      {
       "label": "Sep 3, 2025",
       "cells": [
        "O'NEIL PATRICK R General Counsel",
        "Sell",
        "89.9K",
        "$5.4M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Ionis+Pharmaceuticals%2C+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "Is Ionis Pharmaceuticals (IONS) stock a buy right now?",
   "answer": "Ionis Pharmaceuticals (IONS) is currently trading at $47.25. While Wall Street analysts have a consensus 'Buy' rating and a median price target of $85.00, significant insider selling and significantly oversold technical conditions present considerable risks. The stock's current price is far below its 50-day and 200-day moving averages ($57.95 and $72.74), and its RSI is at an extremely low 7.54."
  },
  {
   "question": "What is the outlook for Ionis Pharmaceuticals (IONS) stock?",
   "answer": "The outlook for Ionis Pharmaceuticals (IONS) is mixed. Analysts project strong revenue growth of 51.00% for next year, which could improve its valuation. However, persistent insider selling and negative profitability metrics pose significant challenges to achieving this growth and reversing the current bearish trend."
  },
  {
   "question": "What are the key risks facing Ionis Pharmaceuticals (IONS)?",
   "answer": "The primary risks for Ionis Pharmaceuticals (IONS) include heavy insider selling totaling over $190 million, significantly oversold technical indicators, and a high price-to-sales ratio of 9.78 compared to the sector median of 3.7. The company also continues to report negative EPS and profit margins."
  },
  {
   "question": "How does Ionis Pharmaceuticals (IONS) compare to its sector peers?",
   "answer": "Ionis Pharmaceuticals (IONS) operates in the Healthcare sector, with a price-to-sales ratio of 9.78, significantly higher than the sector median of 3.7. Its revenue growth is negative at -40.7%, contrasting with the sector median of 8.1%. The company's return on equity is also significantly negative at -105.50%, while the sector median is 6.9%."
  },
  {
   "question": "What is Ionis Pharmaceuticals' (IONS) stock price forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, Ionis Pharmaceuticals' (IONS) stock price forecast for 2030 shows a base case of $58.53, a downside of $18.12, and an upside of $189. These are statistical outcomes, not guaranteed price targets."
  },
  {
   "question": "What is the consensus analyst rating for Ionis Pharmaceuticals (IONS)?",
   "answer": "The consensus analyst rating for Ionis Pharmaceuticals (IONS) is 'Buy', with 24 analysts covering the stock. Nine rate it 'Strong Buy', ten rate it 'Buy', and five rate it 'Hold'. The median price target is $85.00, implying an upside of 79.9% from the current price."
  },
  {
   "question": "What recent news impacts Ionis Pharmaceuticals (IONS)?",
   "answer": "Recent earnings reports for Ionis Pharmaceuticals (IONS) have shown EPS beats in the first quarter of 2026, but these positive results have not translated into stock price gains, indicating broader market concerns may be overshadowing individual earnings performance."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "NVO",
    "name": "Novo Nordisk A/S Sponsored NYSE",
    "price": "$42.53",
    "change": "-2.12%",
    "url": "https://clearank.com/stock/novo-nordisk-nvo/"
   },
   {
    "ticker": "RGNX",
    "name": "Regenxbio Inc. NASDAQ",
    "price": "$7.95",
    "change": "-8.57%",
    "url": "https://clearank.com/stock/rgnx-stock-analysis/"
   },
   {
    "ticker": "OFIX",
    "name": "Orthofix Medical Inc. NASDAQ",
    "price": "$9.09",
    "change": "-0.22%",
    "url": "https://clearank.com/stock/ofix-stock-analysis/"
   },
   {
    "ticker": "CI",
    "name": "The Cigna Group NYSE",
    "price": "$288.98",
    "change": "-0.37%",
    "url": "https://clearank.com/stock/cigna-group-ci/"
   },
   {
    "ticker": "MRK",
    "name": "Merck & Co., Inc. NYSE",
    "price": "$143.17",
    "change": "-1.16%",
    "url": "https://clearank.com/stock/merck-mrk/"
   },
   {
    "ticker": "TMO",
    "name": "Thermo Fisher Scientific Inc. NYSE",
    "price": "$635.29",
    "change": "+3.53%",
    "url": "https://clearank.com/stock/tmo-stock-analysis/"
   },
   {
    "ticker": "ISRG",
    "name": "Intuitive Surgical Inc. NASDAQ",
    "price": "$377.16",
    "change": "-0.21%",
    "url": "https://clearank.com/stock/intuitive-surgical-isrg/"
   },
   {
    "ticker": "SYK",
    "name": "Stryker Corp. NYSE",
    "price": "$281.50",
    "change": "-0.13%",
    "url": "https://clearank.com/stock/stryker-syk/"
   }
  ],
  "comparisons": [
   {
    "ticker": "BSX vs MDT Comparison",
    "name": "",
    "url": "https://clearank.com/compare/bsx-vs-mdt/"
   },
   {
    "ticker": "AAL vs DAL Comparison",
    "name": "",
    "url": "https://clearank.com/compare/aal-vs-dal/"
   },
   {
    "ticker": "SMH vs SOXX Comparison",
    "name": "",
    "url": "https://clearank.com/compare/smh-vs-soxx/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "CCI",
    "text": "Crown Castle Inc.",
    "url": "https://clearank.com/stock/cci-stock-analysis/"
   },
   {
    "ticker": "AME",
    "text": "AMETEK, Inc.",
    "url": "https://clearank.com/stock/ame-stock-analysis/"
   },
   {
    "ticker": "VRSK",
    "text": "Verisk Analytics, Inc.",
    "url": "https://clearank.com/stock/vrsk-stock-analysis/"
   },
   {
    "ticker": "DEO",
    "text": "Diageo plc Sponsored",
    "url": "https://clearank.com/stock/deo-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "SBET",
    "text": "↓ 8.96%",
    "url": "https://clearank.com/stock/sharplink-sbet/"
   },
   {
    "ticker": "CAVA",
    "text": "↓ 8.93%",
    "url": "https://clearank.com/stock/cava-group-cava/"
   },
   {
    "ticker": "ARB/USD",
    "text": "↑ 19.42%",
    "url": "https://clearank.com/crypto/arbitrum-arb-usd/"
   },
   {
    "ticker": "INJ/USD",
    "text": "↓ 11.80%",
    "url": "https://clearank.com/crypto/injective-inj/"
   },
   {
    "ticker": "CRV/USD",
    "text": "↓ 11.53%",
    "url": "https://clearank.com/crypto/crv-usd-crypto-analysis/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "CRNX",
    "text": "Crinetics Pharmaceuticals",
    "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
   },
   {
    "ticker": "CRSP",
    "text": "CRISPR Therapeutics AG",
    "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
   },
   {
    "ticker": "FBRX",
    "text": "Forte",
    "url": "https://clearank.com/stock/fbrx-stock-analysis/"
   },
   {
    "ticker": "LEGN",
    "text": "Legend Biotech",
    "url": "https://clearank.com/stock/legend-biotech-legn/"
   },
   {
    "ticker": "MRNA",
    "text": "Moderna, Inc.",
    "url": "https://clearank.com/stock/moderna-mrna/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/IONS-ionis-pharmaceuticals-analysis-2026-07.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/IONS-ionis-pharmaceuticals-analysis-2026-07.png",
     "width": "1280",
     "height": "720",
     "caption": "Ionis Pharmaceuticals (IONS) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/ions-stock-analysis/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/ions-stock-analysis/",
        "name": "Ionis (IONS) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/ions-stock-analysis/#webpage",
     "url": "https://clearank.com/stock/ions-stock-analysis/",
     "name": "Ionis (IONS) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-10T09:33:18+00:00",
     "dateModified": "2026-09-16T05:16:21+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/IONS-ionis-pharmaceuticals-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/ions-stock-analysis/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/ions-stock-analysis/#richSnippet",
     "headline": "Ionis (IONS) Stock Forecast & Price Target (2026)",
     "name": "Ionis (IONS) Stock Forecast & Price Target (2026)",
     "description": "Ionis Pharmaceuticals, Inc. (IONS) stock: Healthcare, Biotechnology. $7.9B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-07-10T09:33:18+00:00",
     "dateModified": "2026-09-16T05:16:21+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Ionis Pharmaceuticals, Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "IONS"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NASDAQ"
       }
      ],
      "description": "Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on discovering and developing RNA-targeted medicines. Using its proprietary antisense technology, Ionis creates therapies designed to modulate gene expression and address serious diseases, particularly in neurology and c",
      "tickerSymbol": "IONS",
      "sameAs": "https://www.ionis.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/ions-stock-analysis/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/IONS-ionis-pharmaceuticals-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/ions-stock-analysis/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "Is Ionis Pharmaceuticals (IONS) stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Ionis Pharmaceuticals (IONS) is currently trading at $47.25. While Wall Street analysts have a consensus 'Buy' rating and a median price target of $85.00, significant insider selling and significantly oversold technical conditions present considerable risks. The stock's current price is far below its 50-day and 200-day moving averages, and its RSI is at an extremely low 7.54."
     }
    },
    {
     "@type": "Question",
     "name": "What is the outlook for Ionis Pharmaceuticals (IONS) stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The outlook for Ionis Pharmaceuticals (IONS) is mixed. Analysts project strong revenue growth of 51.00% for next year, which could improve its valuation. However, persistent insider selling and negative profitability metrics pose significant challenges to achieving this growth and reversing the current bearish trend."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key risks facing Ionis Pharmaceuticals (IONS)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The primary risks for Ionis Pharmaceuticals (IONS) include heavy insider selling totaling over $190 million, significantly oversold technical indicators, and a high price-to-sales ratio of 9.78 compared to the sector median of 3.7. The company also continues to report negative EPS and profit margins."
     }
    },
    {
     "@type": "Question",
     "name": "How does Ionis Pharmaceuticals (IONS) compare to its sector peers?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Ionis Pharmaceuticals (IONS) operates in the Healthcare sector, with a price-to-sales ratio of 9.78, significantly higher than the sector median of 3.7. Its revenue growth is negative at -40.7%, contrasting with the sector median of 8.1%. The company's return on equity is also significantly negative at -105.50%, while the sector median is 6.9%."
     }
    },
    {
     "@type": "Question",
     "name": "What is Ionis Pharmaceuticals' (IONS) stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Ionis Pharmaceuticals' (IONS) stock price forecast for 2030 shows a base case of $58.53, a downside of $18.12, and an upside of $189. These are statistical outcomes, not guaranteed price targets."
     }
    },
    {
     "@type": "Question",
     "name": "What is the consensus analyst rating for Ionis Pharmaceuticals (IONS)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The consensus analyst rating for Ionis Pharmaceuticals (IONS) is 'Buy', with 24 analysts covering the stock. Nine rate it 'Strong Buy', ten rate it 'Buy', and five rate it 'Hold'. The median price target is $85.00, implying an upside of 79.9% from the current price."
     }
    },
    {
     "@type": "Question",
     "name": "What recent news impacts Ionis Pharmaceuticals (IONS)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Recent earnings reports for Ionis Pharmaceuticals (IONS) have shown EPS beats in the first quarter of 2026, but these positive results have not translated into stock price gains, indicating broader market concerns may be overshadowing individual earnings performance."
     }
    }
   ]
  }
 ]
}